Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial

Authors: Abraham, Prema, Aderman, Christopher, Akiyama, Kunihiko, Alfaro, Daniel V., Ali, Fareed A., Amini, Payam, Anzalotta, Andres Emanuelli, Bátor, György, Batlle, Ivan, Berger, Adam, Bhandari, Ramanath, Bridges, William, Brinkmann, Christian, Brown, Jamin, Burgess, Stuart, Calzada, Jorge, Capone Jr., Antonio, Cervena, Dana, Charles, Steven, Chaudhry, Nauman, Chow, David, Clark, W. Lloyd, Conrad III, Paul, Cunningham, Matthew, Dadgostar, Hajir, Dessouki, Amr, Deupree, Dana, Devine, Christopher, Eichenbaum, David, Ernest, Jan, Feltgen, Nicolas, Fenberg, Moss, Ferrone, Philip, Frenkel, Ronald, Friedman, Scott, Gasperini, Julie, Gerstenblith, Adam, Ghorayeb, Ghassan, Giunta, Michel, Goff, Mitchell, Golas, Liliya, Googe Jr., Joseph M., Goren Fein, Jordana, Hagedorn, Curtis, Hagiwara, Akira, Hahn, Paul, Hairston, Richard, Handza, Jason, Hau, Vivienne, Hayashi, Ken, Heier, Jeffrey, Hershberger, Vrinda, Higgins, Patrick, Hirano, Yoshio, Honda, Shigeru, Ikegami, Yasuko, Ishida, Yuichiro, Ishikawa, Isao, Ishii, Kiyoshi, Jablon, Eric P., Jain, Atul, Kaji, Yuichi, Kapoor, Kapil, Kerényi, Ágnes, Kimura, Kazuhiro, Kishino, Genichiro, Kiss, Katalin, Kitaoka, Takashi, Klancnik, James M., Kobayashi, Namie, Kogo, Jiro, Korda, Vladimir, Kruger, Erik, Kusuhara, Sentaro, Lara, Wilfredo, Laud, Ketan, Lee, Seong, Luu, James, Marcus, Dennis, Mein, Calvin, Meleth, Annal, Milibák, Tibor, Mitamura, Yoshinori, Murata, Toshinori, Noge, Sumiyo, Onoe, Hajime, Osher, James, Papp, András, Parschauer, Justin, Patel, Sugat, Patel, Sunil, Pezda, Matthew, Pirouz, Ashkan, Prasad, Pradeep, Punjabi, Omar, Rao, Llewelyn, Roe, Richard, Schadlu, Ramin, Schneider, Eric, Shah, Ankur, Shah, Milan, Shah, Sandeep, Shah, Sumit, Sharma, Ashish, Sheth, Veeral, Shimura, Masahiko, Singerman, Lawrence, Spital, Georg, Stoltz, Robert, Suan, Eric, Suzuma, Kiyoshi, Takahashi, Hidenori, Takamura, Yoshihiro, Takeuchi, Masaru, Tan, Jeffrey, Thomas, Benjamin, Tóth,-Molnár, Edit, Ueda, Tetsuo, Ushida, Hiroaki, Vajas, Attila, Varma, Deepali, Varsányi, Balázs, Veith, Miroslav, Weber, Pamela, Wee, Raymond, Williams, Geoff, Yamada, Haruhiko, Yonekawa, Yoshihiro, Yoshida, Shigeo, Brown, David M, Boyer, David S, Do, Diana V, Wykoff, Charles C, Sakamoto, Taiji, Win, Peter, Joshi, Sunir, Salehi-Had, Hani, Seres, András, Berliner, Alyson J, Leal, Sergio, Vitti, Robert, Chu, Karen W, Reed, Kimberly, Rao, Rohini, Cheng, Yenchieh, Sun, Wei, Voronca, Delia, Bhore, Rafia, Schmidt-Ott, Ursula, Schmelter, Thomas, Schulze, Andrea, Zhang, Xin, Hirshberg, Boaz, Yancopoulos, George D, Sivaprasad, Sobha ^*

Source: In The Lancet 23-29 March 2024 403(10432):1153-1163

Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial

Authors: Lanzetta, Paolo ^*, Korobelnik, Jean-François ^*, Heier, Jeffrey S ^*, Leal, Sergio, Holz, Frank G, Clark, W Lloyd, Eichenbaum, David, Iida, Tomohiro, Xiaodong, Sun, Berliner, Alyson J, Schulze, Andrea, Schmelter, Thomas, Schmidt-Ott, Ursula, Zhang, Xin, Vitti, Robert, Chu, Karen W, Reed, Kimberly, Rao, Rohini, Bhore, Rafia, Cheng, Yenchieh, Sun, Wei, Hirshberg, Boaz, Yancopoulos, George D, Wong, Tien Y

Source: In The Lancet 23-29 March 2024 403(10432):1141-1152

Intravitreal Nesvacumab (Antiangiopoietin 2) Plus Aflibercept in Diabetic Macular Edema: Phase 2 Ruby Randomized Trial

Authors: Brown, David M., Boyer, David S., Csaky, Karl, Vitti, Robert, Perlee, Lorah, Chu, Karen W., Asmus, Friedrich, Leal, Sergio, Zeitz, Oliver, Cheng, Yenchieh

Source: Retina. 42(6):1111-1120

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN632186252&indx=1&recIds=ETOCRN632186252

Intravitreal Combined Aflibercept + Anti–Platelet-Derived Growth Factor Receptor β for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial

Authors: Heier, Jeffrey S., Wykoff, Charles C., Waheed, Nadia K., Kitchens, John W., Patel, Sunil S., Vitti, Robert, Perlee, Lorah, Chu, Karen W., Leal, Sergio, Asmus, Friedrich, Son, Vladimir, Schmelter, Thomas, Brown, David M.

Source: In Ophthalmology February 2020 127(2):211-220

Long-term Safety and Visual Outcome of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration: VIEW 1 Extension Study

Authors: Kaiser, Peter K., Singer, Michael, Tolentino, Michael, Vitti, Robert, Erickson, Kristine, Saroj, Namrata, Berliner, Alyson J., Chu, Karen W., Zhu, Xiaoping, Williams Liu, Zinaria, Clark, W. Lloyd

Source: In Ophthalmology Retina July-August 2017 1(4):304-313

Effects of Repeated Intravitreal Aflibercept Injection on the Corneal Endothelium in Patients With Age-Related Macular Degeneration: Outcomes From the RE-VIEW Study

Authors: Lass, Jonathan H., Benetz, Beth Ann, Menegay, Harry J., Tsipis, Constantinos P., Cook, Jane Caty, Boyer, David S., Singer, Michael, Erickson, Kristine, Saroj, Namrata, Vitti, Robert, Chu, Karen W., Moini, Hadi, Soo, Yuhwen, Cheng, Yenchieh

Source: Cornea. 37(5):596-601

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100189985323.0x000001&indx=1&recIds=ETOCvdc_100189985323.0x000001

Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study

Authors: Clark, W. Lloyd, Boyer, David S., Heier, Jeffrey S., Brown, David M., Haller, Julia A., Vitti, Robert, Kazmi, Husain, Berliner, Alyson J., Erickson, Kristine, Chu, Karen W., Soo, Yuhwen, Cheng, Yenchieh, Campochiaro, Peter A.

Source: In Ophthalmology February 2016 123(2):330-336

Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.

Authors: Brown, David M¹, Boyer, David S², Do, Diana V³, Wykoff, Charles C^1,4, Sakamoto, Taiji⁵, Win, Peter⁶, Joshi, Sunir⁷, Salehi-Had, Hani⁸, Seres, András⁹, Berliner, Alyson J¹⁰, Leal, Sergio¹¹, Vitti, Robert¹⁰, Chu, Karen W¹⁰, Reed, Kimberly¹⁰, Rao, Rohini¹⁰, Cheng, Yenchieh¹⁰, Sun, Wei¹⁰, Voronca, Delia¹⁰, Bhore, Rafia¹⁰, Schmidt-Ott, Ursula¹²

Source: Lancet; Mar2024, Vol. 403 Issue 10432, p1153-1163, 11p

Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: The 24-Week Results of the VIBRANT Study

Authors: Campochiaro, Peter A., Clark, W. Lloyd, Boyer, David S., Heier, Jeffrey S., Brown, David M., Vitti, Robert, Kazmi, Husain, Berliner, Alyson J., Erickson, Kristine, Chu, Karen W., Soo, Yuhwen, Cheng, Yenchieh, Haller, Julia A.

Source: In Ophthalmology March 2015 122(3):538-544

Sustained disease control with aflibercept 8 mg: a new benchmark in the management of retinal neovascular diseases

Authors: Korobelnik, Jean-François, Lanzetta, Paolo, Wykoff, Charles C., Wong, Tien Y., Zhang, Xin, Morgan-Warren, Peter, Fitzpatrick, Scott, Leal, Sergio, Brunck, Lynne, Hasanbasic, Zoran, Chu, Karen W., Reed, Kimberly, Sivaprasad, Sobha

Source: Eye; 20240101, Issue: Preprints p1-4, 4p

Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.

Authors: Wykoff, Charles C., Brown, David M., Reed, Kimberly, Berliner, Alyson J., Gerstenblith, Adam T., Breazna, Aurora, Abraham, Prema, Fein, Jordana G., Chu, Karen W., Clark, W. Lloyd, Leal, Sergio, Schmelter, Thomas, Hirshberg, Boaz, Yancopoulos, George D., Vitti, Robert

Source: JAMA Ophthalmology; Sep2023, Vol. 141 Issue 9, p834-842, 9p

THERAPEUTIC REGIMEN FOR TREATING CANCER

THERAPEUTIC REGIMEN FOR TREATING CANCER

THERAPEUTIC REGIMEN FOR TREATING CANCER

THERAPEUTIC REGIMEN FOR TREATING CANCER

Intravitreal Nesvacumab (Anti-Angiopoietin-2) Plus Aflibercept in Neovascular AMD: Phase 2 ONYX Randomized Trial

Authors: Heier, Jeffrey S., Ho, Allen C., Boyer, David S., Csaky, Karl, Vitti, Robert, Perlee, Lorah, Chu, Karen W., Asmus, Friedrich, Leal, Sergio, Zeitz, Oliver, Cheng, Yenchieh, Schmelter, Thomas, Brown, David M.

Source: Journal of VitreoRetinal Diseases; January 2023, Vol. 7 Issue: 1 p8-15, 8p

THERAPEUTIC REGIMEN FOR TREATING CANCER

Therapeutic regimen for treating cancer comprising the administration of adenoviral vectors comprising a TNF-α transgene

Therapeutic regimen for treating cancer

Reply

Authors: Clark, W. Lloyd, Boyer, David S., Heier, Jeffrey S., Brown, David M., Haller, Julia A., Vitti, Robert, Kazmi, Husain, Berliner, Alyson J., Erickson, Kristine, Chu, Karen W., Soo, Yuhwen, Cheng, Yenchieh, Campochiaro, Peter A.

Source: In Ophthalmology October 2016 123(10):e60-e61